CN101327206A - 一种多西他赛注射液及其制备方法 - Google Patents
一种多西他赛注射液及其制备方法 Download PDFInfo
- Publication number
- CN101327206A CN101327206A CNA2007100493579A CN200710049357A CN101327206A CN 101327206 A CN101327206 A CN 101327206A CN A2007100493579 A CNA2007100493579 A CN A2007100493579A CN 200710049357 A CN200710049357 A CN 200710049357A CN 101327206 A CN101327206 A CN 101327206A
- Authority
- CN
- China
- Prior art keywords
- docetaxel
- standby
- filter membrane
- stir
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 52
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 51
- 238000002347 injection Methods 0.000 title claims abstract description 24
- 239000007924 injection Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002841 Lewis acid Substances 0.000 claims abstract description 16
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 238000003756 stirring Methods 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 239000012528 membrane Substances 0.000 claims description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 238000001914 filtration Methods 0.000 claims description 33
- 238000007689 inspection Methods 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 229920000136 polysorbate Polymers 0.000 claims description 20
- 229950008882 polysorbate Drugs 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 14
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 12
- 210000004907 gland Anatomy 0.000 claims description 12
- 239000011265 semifinished product Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 4
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 4
- 229940101027 polysorbate 40 Drugs 0.000 claims description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 62
- 229960004756 ethanol Drugs 0.000 description 25
- 229940090044 injection Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 239000008155 medical solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000011169 microbiological contamination Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100493579A CN101327206B (zh) | 2007-06-22 | 2007-06-22 | 一种多西他赛注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100493579A CN101327206B (zh) | 2007-06-22 | 2007-06-22 | 一种多西他赛注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101327206A true CN101327206A (zh) | 2008-12-24 |
CN101327206B CN101327206B (zh) | 2011-07-20 |
Family
ID=40203363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100493579A Expired - Fee Related CN101327206B (zh) | 2007-06-22 | 2007-06-22 | 一种多西他赛注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101327206B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102451155A (zh) * | 2010-10-26 | 2012-05-16 | 海南中化联合制药工业股份有限公司 | 一种多西他赛注射液处方及制备方法 |
CN104546694A (zh) * | 2013-10-15 | 2015-04-29 | 悦康药业集团有限公司 | 一种多西他赛注射液及其制备方法 |
CN107157926A (zh) * | 2017-07-20 | 2017-09-15 | 四川汇宇制药有限公司 | 一种多西他赛注射剂的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0517092D0 (en) * | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
-
2007
- 2007-06-22 CN CN2007100493579A patent/CN101327206B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102451155A (zh) * | 2010-10-26 | 2012-05-16 | 海南中化联合制药工业股份有限公司 | 一种多西他赛注射液处方及制备方法 |
CN104546694A (zh) * | 2013-10-15 | 2015-04-29 | 悦康药业集团有限公司 | 一种多西他赛注射液及其制备方法 |
CN107157926A (zh) * | 2017-07-20 | 2017-09-15 | 四川汇宇制药有限公司 | 一种多西他赛注射剂的制备方法 |
CN107157926B (zh) * | 2017-07-20 | 2020-08-21 | 四川汇宇制药股份有限公司 | 一种多西他赛注射剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101327206B (zh) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104323986A (zh) | 一种间苯三酚注射液及其制备方法 | |
CN101327206B (zh) | 一种多西他赛注射液及其制备方法 | |
CN103989630B (zh) | 盐酸莫西沙星氯化钠注射液及其制备方法 | |
CN108186559A (zh) | 胱氨酸注射剂及其制备工艺 | |
CN101190214B (zh) | 紫杉醇注射液及其制备方法 | |
CN102716076B (zh) | 一种供注射用的盐酸氨溴索药物组合物 | |
CN102100666A (zh) | 一种新的盐酸莫西沙星注射剂 | |
CN101584659B (zh) | 一种多西他赛药物组合物注射剂及其制备方法 | |
CN102718693B (zh) | 一种卡络磺钠化合物及其组合物 | |
CN105125484A (zh) | 一种无痛化的多西环素注射液及其制备方法 | |
CN101507747B (zh) | 黄芪总皂苷氯化钠注射液的制备方法 | |
CN102688248B (zh) | 蟾蜍甾烯类化合物在制备治疗口腔黏膜恶性肿瘤药物中的应用 | |
CN108653203A (zh) | 可用于静脉注射的人参皂苷Rk3制剂及制备方法 | |
CN105193712B (zh) | 盐酸氨溴索注射液和制法 | |
CN107334731A (zh) | 一种牛用二丙酸咪唑苯脲注射液及其制备方法和应用 | |
CN1919339A (zh) | 含有蛋白的葫芦素纳米制剂及制备方法和用途 | |
CN102793663B (zh) | 一种含抗肿瘤药物2-甲氧基雌二醇的缓释微球注射剂 | |
CN102335129B (zh) | 一种供注射用依达拉奉药物组合物及其制备方法 | |
CN1231223C (zh) | 灯盏花素输液制剂及其制备方法 | |
CN109044969B (zh) | 一种紫杉醇注射液的制备方法 | |
CN102406605A (zh) | 雄性激素类药物的醇质体制剂及其制备方法 | |
CN102793678B (zh) | 一种不含吐温的多烯紫杉醇注射剂的制备方法 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN1270702C (zh) | 辅酶q10静脉输液及其制备方法 | |
CN103432067A (zh) | 酮洛芬溶液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Bing Document name: Notification that Application Deemed to be Withdrawn |
|
ASS | Succession or assignment of patent right |
Owner name: CHENGDU YISI BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GAO BING Effective date: 20110315 Free format text: FORMER OWNER: SU XIUFANG SHU LING |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610031 NO. 2, SHUMING WEST ROAD, JINNIU DISTRICT, CHENGDU CITY, SICHUAN PROVINCE TO: 610036 UNIT 4, BUILDING 8, XICHENG INTERNATIONAL, NO. 48, SHUXI ROAD, JINNIU DISTRICT, CHENGDU CITY, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110315 Address after: 610036, 4, 8, Xicheng, 48, West Shu Road, Jinniu District, Sichuan, Chengdu Applicant after: Chengdu Yisi Biotechnology Co., Ltd. Address before: 610031, No. 2 Shu Ming West Road, Chengdu, Sichuan, Jinniu District Applicant before: Gao Bing Co-applicant before: Su Xiufang Co-applicant before: Shu Ling |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU TIANDI RENHE MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: CHENGDU YISI BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20120120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610036 CHENGDU, SICHUAN PROVINCE TO: 610017 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120120 Address after: 7, building 610017, building B4, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee after: CHENGDU TIANDI RENHE PHARMACEUTICAL RESEARCH CO., LTD. Address before: 610036, 4, 8, Xicheng, 48, West Shu Road, Jinniu District, Sichuan, Chengdu Patentee before: Chengdu Yisi Biotechnology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: CHENGDU YONGRUN INVESTMENT CONSULTING CO., LTD. Free format text: FORMER OWNER: CHENGDU TIANDI RENHE MEDICINE RESEARCH CO., LTD. Effective date: 20120830 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610017 CHENGDU, SICHUAN PROVINCE TO: 610043 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120830 Address after: 610043, No. 4, No. 1, 24, 179 Ling Ling Road, Sichuan, Chengdu, Wuhou District Patentee after: Chengdu Yong run Cci Capital Ltd Address before: 7, building 610017, building B4, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee before: CHENGDU TIANDI RENHE PHARMACEUTICAL RESEARCH CO., LTD. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20180622 |
|
CF01 | Termination of patent right due to non-payment of annual fee |